8 min

Improving outcomes for oestrogen receptor positive breast cancer IFCPE 2017

    • Medicine

Dr Pruneri talks to ecancer at IFCPE 2017 about treating the 20% of oestrogen-receptor positive breast cancer patients who relapse following first-line treatments.

He describes how comparative genotyping of primary tumours and subsequent lesions could reveal treatment resistance, giving the example of recent research exposing aromatase inhibitor resistance.

Dr Pruneri talks to ecancer at IFCPE 2017 about treating the 20% of oestrogen-receptor positive breast cancer patients who relapse following first-line treatments.

He describes how comparative genotyping of primary tumours and subsequent lesions could reveal treatment resistance, giving the example of recent research exposing aromatase inhibitor resistance.

8 min

Top Podcasts In Medicine

More by ecancer